Finasteride 5 mg for BPH

Finasteride blocks type II 5-alpha reductase, the enzyme that converts testosterone into dihydrotestosterone. That one action carries two entirely separate FDA approvals. The 5 mg tablet was approved on June 19, 1992 under application NDA 020180, for an enlarged prostate. The 1 mg tablet followed five years later, on December 19, 1997 under NDA 020788, for hair loss. Same molecule, same original sponsor, two labels that were written for different bodies and different problems.

The wording diverges immediately. The 5 mg label is indicated for symptomatic benign prostatic hyperplasia in men with an enlarged prostate, to improve symptoms and to reduce the risk of acute urinary retention and of BPH surgery. The 1 mg label is indicated for male pattern hair loss in men only, and says efficacy in bitemporal recession has not been established. Neither label claims the other indication. The 5 mg label also carries a limitation of use stating it is not approved for the prevention of prostate cancer.

The FDA National Drug Code directory lists finished finasteride tablets at exactly two strengths in the United States, 1 mg and 5 mg, with the large majority of listings filed as abbreviated generic applications rather than the two original brands. There is no 2.5 mg product and no half-dose presentation. That gap is why this page exists.

The arithmetic of getting a 1 mg dose out of a 5 mg tablet is obvious the moment the two strengths sit next to each other, and both labels have something to say about it.

The registration evidence for the 5 mg dose is the four year PLESS study. It randomized 3,040 men between 45 and 78 with moderate to severe BPH symptoms and an enlarged prostate on rectal examination, 1,524 to finasteride and 1,516 to placebo. Men who stayed on treatment for four years had a mean symptom score fall of 3.3 points against 1.3 on placebo, on a 0 to 34 scale where the group started around 15. The separation was already statistically significant at one year.

The harder endpoints matter more than the score. Acute urinary retention requiring catheterization or BPH-related surgery occurred in 6.6% on finasteride against 13.2% on placebo, a 51% reduction in risk. Surgical intervention alone ran 4.6% against 10.1%, and retention alone 2.8% against 6.6%. All treatment failures, a broader composite, came to 26.2% against 37.1%. Those are absolute numbers over four years in men who already had an enlarged prostate. No projection involved.

Timing is the part that gets skipped. The label states that although some early symptom improvement is seen, a therapeutic trial of at least six months is generally necessary to judge whether symptom relief has been achieved. It also asks that other urological conditions be considered before starting, because prostate cancer and BPH can coexist, and that men with a large residual urine volume or severely reduced flow be watched for obstructive uropathy. A licensed clinician decides whether any of that fits you.

This is the question the whole page turns on, and it was answered before the 1 mg product existed. Two dose ranging studies gave men with vertex hair loss finasteride at 5 mg, 1 mg, 0.2 mg or 0.01 mg a day or placebo, and found efficacy at 0.2 mg and above, with 1 mg and 5 mg showing similar efficacy that was superior to the lower doses. The 0.01 mg arm looked like placebo. The published conclusion was that 1 mg a day is the optimal dose for male pattern hair loss. The pharmacology explains why the curve flattens. A 1 mg tablet produces a rapid fall in serum dihydrotestosterone, reaching 65% suppression within 24 hours of dosing. Push past that and there is not much dihydrotestosterone left to remove. In the hair loss trials, 1 mg produced a 107 hair difference from placebo at 12 months within a one inch circle, widening to 138 hairs at two years, with improvement visible as early as three months and effect reversing within 12 months of stopping.

So the premise behind reaching for the bigger tablet does not hold on the published dose response. Five times the milligrams did not produce five times the hair, or even measurably more hair, in the trials that set the dose. What extra milligrams reliably buy is extra systemic exposure to a drug whose adverse effect profile was characterized separately in each indication. That tradeoff belongs to a prescriber, and this page is not telling you to make it.

Finasteride is contraindicated in females who are or may potentially be pregnant. The 5 mg label states that based on animal studies and the mechanism of action, finasteride may cause abnormal development of the external genitalia in a male fetus if given to a pregnant female, and notes that in female rats low doses during pregnancy produced abnormalities of the external genitalia in male offspring.

The human wording is a mechanism-based warning, and the rat data sits beside it as a separate line of evidence.

The handling clause is where splitting stops being a dosing question. Both labels state that the tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have not been broken or crushed, and that a female who is or may become pregnant should not handle crushed or broken tablets. The same wording appears on the 1 mg label, with the instruction to wash the contact area immediately with soap and water. A broken tablet in a shared home stops being a private exposure.

Read together, that leaves the coating doing all the protective work, and dividing a tablet is exactly what removes it. The 5 mg dosing section reads one tablet (5 mg) taken once a day, with or without meals, and the 1 mg dosing section reads one tablet (1 mg) taken once daily. Neither describes a score line, a half dose, or any instruction for dividing. If your reason for asking involves a different dose than the one on the label you hold, that belongs in front of a prescriber.

This is the most consequential thing on the page. The 5 mg label states that finasteride reduces serum prostate specific antigen by approximately 50%, and that to interpret an isolated PSA value after six months or more of treatment, the value should be doubled before comparing it with normal ranges for untreated men. It adds that any confirmed increase from the lowest PSA value reached on treatment may signal prostate cancer and should be evaluated even when the number still sits inside the normal range.

The doubling rule is a floor, not a constant. An analysis of serial PSA in the Prostate Cancer Prevention Trial found that the adjustment factor required to preserve median PSA rose from 2 at 24 months to 2.5 at seven years after starting finasteride, and concluded that time varying adjustment is needed beyond the first year. In men without cancer on end of study biopsy, PSA on finasteride drifted down about 2% a year while the control arm drifted up about 3%.

Two practical consequences. First, whoever reads your next PSA has to know that you take finasteride and for how long, because the correction depends on duration. Second, the 1 mg product moves the number too: in the hair loss trials in men aged 18 to 41, mean PSA fell from 0.7 ng/mL at baseline to 0.5 ng/mL at month 12. The 5 mg label also notes that the ratio of free to total PSA stays constant under finasteride, which is why percent free PSA remains usable.

Both labels carry the same warning, and it comes from the 5 mg dose. Men aged 55 and over with a normal rectal examination and PSA at or below 3.0 ng/mL who took finasteride 5 mg a day in the seven year Prostate Cancer Prevention Trial had a higher rate of Gleason 8 to 10 prostate cancer, 1.8% against 1.1% on placebo. The 1 mg label repeats the finding and points out that this was five times the 1 mg dose. The 5 mg label states plainly that the drug is not approved for the prevention of prostate cancer.

The original 2003 report randomized 18,882 men to finasteride 5 mg or placebo for seven years, with biopsy recommended when the finasteride-adjusted PSA exceeded 4.0 ng/mL or the rectal examination was abnormal. A follow-up published in 2013 tracked the same cohort for up to 18 years: prostate cancer was diagnosed in 10.5% of the finasteride group against 14.9% of the placebo group, relative risk 0.70, while high grade disease, defined in that follow-up as Gleason 7 to 10 rather than the Gleason 8 to 10 on the label, ran 3.5% against 3.0%, relative risk 1.17 with an interval of 1.00 to 1.37.

The survival data is the part that rarely gets quoted. Fifteen year survival was 78.0% in the finasteride group and 78.2% on placebo, with an unadjusted hazard ratio for death of 1.02. Among men who did develop high grade cancer, ten year survival was 73.0% against 73.6%. The signal in the biopsy data did not translate into a mortality difference across nearly two decades. The warning still sits on the label, and how much weight it deserves in your case is a conversation with a clinician.

The same drug reports very different adverse effect rates depending on who was enrolled. In the BPH combination trial, mean age 62.6, the finasteride arm reported impotence in 18.5% against 12.2% on placebo, decreased libido 10.0% against 5.7%, and abnormal ejaculation 7.2% against 2.3%. In the four year PLESS study, first year rates were impotence 8.1% against 3.7% and decreased libido 6.4% against 3.4%, with no significant difference between groups in years two through four.

The 1 mg trials enrolled men aged 18 to 41, and reported first year drug-related rates of decreased libido 1.8% against 1.3%, erectile dysfunction 1.3% against 0.7%, and ejaculation disorder 1.2% against 0.7%. Across the integrated analysis, 3.8% of the finasteride group against 2.1% of placebo reported one or more, the incidence of each fell to 0.3% or lower by year five, and resolution occurred both in men who stopped and in most who continued. Discontinuation for a sexual adverse experience ran 1.2% against 0.9%.

Do not read those two sets of numbers as a dose comparison. Both labels carry the standard caution that adverse reaction rates from different trials cannot be directly compared, and the populations differ by three decades of age and by baseline urological health. A meta-analysis of 15 randomized, double blind, placebo-controlled hair loss trials covering 4,495 subjects put the relative risk of sexual dysfunction at 1.57 for 5-alpha reductase inhibitors and 1.66 for finasteride specifically. The 1 mg label also records postmarketing reports of sexual dysfunction continuing after the drug was stopped.

The 5 mg label carries a second indication that the 1 mg label has no equivalent of. Finasteride given with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic BPH progression, defined as a confirmed four point or greater rise in American Urological Association symptom score. The evidence is a trial of 3,047 men with symptomatic BPH randomized to finasteride 5 mg, doxazosin at 4 or 8 mg, both, or placebo for four to six years, mean age 62.6 and mean prostate volume 36.3 mL.

Against placebo, the reduction in risk of the composite endpoint was 34% for finasteride, 39% for doxazosin and 67% for the combination, and the combination beat finasteride alone by a further 49% and doxazosin alone by 46%. In raw counts, primary outcome events hit 17.4% on placebo, 11.6% on finasteride, 11.2% on doxazosin and 6.2% on the combination. Acute urinary retention specifically ran 2.4% on placebo against 0.8% on finasteride and 0.5% on the combination.

The combination is not free. Dizziness was reported by 23.2% on combination therapy against 8.1% on placebo, postural hypotension 17.8% against 8.0%, asthenia 16.8% against 7.1%, and abnormal ejaculation 14.1% against 2.3%. The label notes that abnormal ejaculation on combination was roughly the sum of the two monotherapies rather than something new. Whether the extra protection is worth the extra symptom load is exactly the kind of tradeoff a prescriber weighs against your own symptom score.

The federal National Average Drug Acquisition Cost file records what United States retail pharmacies actually pay to buy a drug, which makes it the cleanest public number for comparing two strengths of the same molecule. In the file published on September 2, 2026, a generic finasteride 5 mg tablet costs pharmacies $0.06839 and a generic 1 mg tablet costs $0.04260, both classified as generic. The brand versions in the same file run $5.70733 for the 5 mg tablet and between $3.58511 and $3.96500 for the 1 mg, across its two listings.

Annualize it and the picture sharpens. A 1 mg tablet daily for a year is about $15.55 of acquisition cost. A whole 5 mg tablet daily for a year is about $24.96. The brand 1 mg tablet daily for a year is roughly $1,309, which is 84 to 93 times the generic. All four figures come from the same 2026 file, so the comparison holds constant everything except strength and brand status. What you are charged at a counter or by a subscription service is a separate number that this file does not measure.

Now the arbitrage that drives the question. A quarter of a generic 5 mg tablet carries about 1.7 cents of acquisition cost against 4.3 cents for a generic 1 mg tablet, a gap of roughly two and a half cents a day, or about nine dollars a year. That is the entire financial case, at acquisition cost, for a practice that removes the coating both labels rely on and that neither label describes.

Set that nine dollars beside the handling rules above before it looks like a bargain.

The 5 mg label sets its own gate before a prescription is written. It asks that other urological conditions be considered first, notes that prostate cancer and BPH can coexist, and says men with a large residual urine volume or severely reduced urinary flow should be monitored for obstructive uropathy and may not be candidates. Those are the checks of a urological evaluation, and a web form does not perform them. Online services can and do treat BPH, but the assessment behind the prescription is what determines whether the prescription is the right one.

Criteria worth applying to any prescriber, online or in person. Does the intake record which indication is being treated, since the two labels differ. Does it capture a baseline PSA and the date treatment started, so the doubling correction can be applied later. Does it note the correction in your record where a future reader will find it. Does a named, licensed clinician review the file. Is dispensing done by a United States licensed pharmacy. Is your record re-reviewed before a renewal rather than auto-shipped.

This article is informational and is not medical advice. What is appropriate for you is a prescribing decision, and results vary from one person to the next.

One more question, and it is the one this page was built around. If your interest in the 5 mg tablet is really about hair, say so out loud, because the dose response, the adverse effect data and the handling rules all read differently once the actual goal is on the table.